NIR Diagnostics Signs Regional Agreement With European Medical Device Distributor For HemoNIR

Campbellville, ON - NIR Diagnostics Inc., an innovator in the development of handheld healthcare diagnostic devices, announced recently that it has signed a regional distribution agreement for its portable CO-oximeter device, HemoNIR, with a European based medical device distributor company. The multi-year agreement stipulates that the Distributor must meet a defined set of sales performance criteria. NIR Diagnostics is currently not disclosing the name of the Distributor pending the completion of negotiations with North American medical device companies also interested in distribution rights to HemoNIR.

"The recent interest in our in-vitro handheld hemoglobin technology from global distributors is predominantly due to the growing awareness of the capability of our technology, as well as consolidation within the hemoglobin detection diagnostics industry," said Duncan J. MacIntyre, President, Chief Executive Officer and Executive Vice Chairman of NIR Diagnostics. "The accuracy and ease-of-use of our technology as well as the broad range of monitoring options arising from both our in-vitro and in-vivo platforms is driving renewed interest in HemoNIR. In particular, significant interest has been expressed in the application of our technology for the detection of bilirubin for use in neonatal clinics and we are exploring the addition of such capability to our existing HemoNIR device."

HemoNIR is a handheld portable CO-oximeter that has received market clearance from the U.S. Food and Drug Administration and a medical device licence from Health Canada. It enables the user to monitor Total Hemoglobin, Met-Hemoglobin and Carboxy-Hemoglobin from a single droplet of blood. HemoNIR does not require direct interaction with the sample or the use of chemical reagents and is capable of detecting anemia, carbon monoxide poisoning, smoke inhalation, drugs, chemicals, and enzyme deficiency.

NIR Diagnostics continues to work with Lifescan specifically in relation to its in-vitro detection of glucose, as previously disclosed.

SOURCE: NIR Diagnostics Inc.